{
    "nctId": "NCT06519370",
    "briefTitle": "FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer",
    "officialTitle": "A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 350,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients capable to give written informed consent;\n2. Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. Triple negative is defined as \\<1% expression for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization;\n3. Prior exposure to a taxane in localized or advanced/metastatic setting, and recurred during or after treatment;\n4. Eligible for one of the chemotherapy options listed as ICC (eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment;\n5. Have measurable lesions defined in RECIST v.1.1, those with only skin or bone lesions cannot be included;\n6. Expected survival\u22653 months;\n7. Eastern Cancer Cooperative Group (ECOG) performance status 0-1;\n8. Adequate bone marrow, hepatic, and renal function;\n9. All acute toxicity of previous anti-tumor treatment or surgery is relieved to baseline severity or NCI CTCAE version 5.0\u22641;\n10. Subjects could provide tumor tissues or tissue specimens;\n11. Patients of child bearing potential must agree to take contraception during the study and for 6 months after the last day of treatment.\n\nExclusion Criteria:\n\n1. Patients with other malignancies, except cured basal or squamous cell skin cancer or in situ cancer of cervix; and patients with other malignancies must have a tumor-free period of at least 5 years;\n2. Have central nervous system metastasis with clinical symptoms;\n3. Have history of clinical significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months prior to the first dose;\n4. Suffering from active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease), and history of intestinal obstruction, or Gl perforation;\n5. Patients with Gilbert's disease or heterozygous for the UGT1A1\\*28 allele;\n6. Participants known to be human immunodeficiency (HIV) positive, hepatitis B positive, or hepatitis C positive;\n7. Patients who have received prior TROP-2-targeted therapy;\n8. Patients who have received prior topoisomerase I inhibitor contained therapy;\n9. Received other anti-tumor treatments (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, experimental treatment and so on) within 4 weeks prior to the first dose;\n10. Patients who have received live vaccines within 4 weeks prior to the first dose;\n11. Patients who had undergone major surgery or severe trauma within 4 weeks prior to the first dose;\n12. Patients who had undergone systemic high-dose steroids within 2 weeks prior to the first dose;\n13. Patients have history of psychotropic drug abuse, alcohol or drug abuse;\n14. Women who are pregnant or lactating;\n15. Other circumstances that is deemed not appropriate for the study by investigator.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}